{
    "clinical_study": {
        "@rank": "14933", 
        "arm_group": {
            "arm_group_label": "pemetrexed", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "PFS"
        }, 
        "brief_title": "A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers", 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        .\u226565 years or PS 2\n\n          -  Patients who were diagnosed by the histologic, cytologic diagnosis of IV non-small\n             cell lung cancer\n\n          -  Patients received no chemical therapy or only received targeted therapy,and there is\n             evidence show the patent is PD\n\n          -  Presence of at least one index lesion measurable by CT scan or MRI\n\n               -  leucocyte \u2265 3.5\u00d7109/L\n\n               -  neutrophil \u2265 1.5\u00d7109/L\n\n               -  platelet \u2265 80\u00d7109/L\n\n               -  Hemoglobin \u2265 9g/L\n\n               -  ALT and AST \u2264 2.5\u00d7ULN ,Tbil\u2264 1.5\u00d7ULN\n\n          -  BUN\u2264 1.5\u00d7ULN\n\n          -  Signed written informed consent\n\n        Exclusion Criteria:\n\n          -  squamous carcinoma or small cell lung cancer\n\n          -  Patients were allergic to pemetrexed\n\n          -  Patients received chemotherapy before\n\n          -  Uncontrolled acute infection\n\n             .Uncontrolled pleural effusion\n\n          -  Severe symptomatic heart disease\n\n          -  Severe infection or metabolic disfunction\n\n          -  Patients with other malignant tumor\n\n          -  Uncontrolled brain metastases\n\n          -  Patients have accepted other clinical trials\n\n          -  Female patients during their pregnant and lactation period, or patients without\n             contraception\n\n               -  Mental disorientation of disorder\n\n               -  Glucocorticoids taboo"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "70 Years"
        }, 
        "enrollment": {
            "#text": "94", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860508", 
            "org_study_id": "2013-PEM-WJL"
        }, 
        "intervention": {
            "arm_group_label": "pemetrexed", 
            "intervention_name": "pemetrexed /carboplatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Progression free Survival", 
        "lastchanged_date": "July 4, 2013", 
        "location": {
            "contact": {
                "email": "luwangjialei@hotmail.com", 
                "last_name": "Jia lei Wang, Master", 
                "phone": "02164175590", 
                "phone_ext": "8907"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Cancer hospital Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Advanced Metastatic Non-small Cell Lung Cancer Patients Aged or PS Score 2 Points for First Line Application Pemetrexed/Carboplatin Chemotherapy Regimens Sequential Pemetrexed Single Drug Maintenance Treatment of Clinical Research and Related Predictive Biomarkers of Exploratory Research", 
        "overall_contact": {
            "email": "luwangjialei@hotmail.com", 
            "last_name": "Jia lei Wang, Master", 
            "phone": "02164175590", 
            "phone_ext": "8907"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PFS", 
            "safety_issue": "No", 
            "time_frame": "from the first cycle of treatment (day one) to two month after the last cycle"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860508"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Jialei Wang", 
            "investigator_title": "Attending doctor of medical oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}